U18666A, an intra-cellular cholesterol transport inhibitor, inhibits dengue virus entry and replication

Antiviral Res. 2012 Jan;93(1):191-8. doi: 10.1016/j.antiviral.2011.11.014. Epub 2011 Nov 29.

Abstract

The level of cholesterol in host cells has been shown to affect viral infection. However, it is still not understood why this level of regulation is important for successful infection. We have shown in this study that dengue virus infection was affected when the cholesterol intake in infected cells was disrupted using a cholesterol transport inhibitor, U18666A. The antiviral effect was found to result from two events: retarded viral trafficking in the cholesterol-loaded late endosomes/lysosomes and suppressed de novo sterol biosynthesis in treated infected cells. We also observed an additive antiviral effect of U18666A with C75, a fatty acid synthase inhibitor, suggesting dengue virus relies on both the host cholesterol and fatty acid biosynthesis for successful replication.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 4-Butyrolactone / analogs & derivatives
  • 4-Butyrolactone / pharmacology
  • Androstenes / pharmacology*
  • Animals
  • Anticholesteremic Agents / pharmacology*
  • Antiviral Agents / pharmacology*
  • Biological Transport / drug effects
  • Cell Line
  • Cholesterol / metabolism*
  • Cricetinae
  • Dengue Virus / drug effects*
  • Drug Synergism
  • Endosomes / drug effects
  • Endosomes / metabolism
  • Fatty Acid Synthases / antagonists & inhibitors
  • Humans
  • Lysosomes / drug effects
  • Lysosomes / metabolism
  • Virus Internalization / drug effects*
  • Virus Replication / drug effects*

Substances

  • 4-methylene-2-octyl-5-oxofuran-3-carboxylic acid
  • Androstenes
  • Anticholesteremic Agents
  • Antiviral Agents
  • 3-beta-(2-(diethylamino)ethoxy)androst-5-en-17-one
  • Cholesterol
  • Fatty Acid Synthases
  • 4-Butyrolactone